Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14864559 | 0.87 | GRIN1 (0.41) | KCNH2KMT2AMEN1 | |
| SCHEMBL14864562 | 0.80 | KCNH2 (0.51) | KCNH2ADRB3NPC1 | |
| SCHEMBL2018556 | 0.79 | KCNH2 (0.66) | KCNH2ADRB3 | |
| SCHEMBL2018559 | 0.79 | KCNH2 (0.66) | KCNH2ADRB3 | |
| SCHEMBL2018558 | 0.79 | KCNH2 (0.66) | KCNH2ADRB3 | |
| SCHEMBL14864558 | 0.72 | MAPT (0.52) | ADRB3KMT2AMEN1MAPT | |
| SCHEMBL14864500 | 0.70 | KCNH2 (0.50) | KCNH2ADRB3 | |
| SCHEMBL14864494 | 0.70 | MEN1 (0.55) | KCNH2KMT2AMEN1MAPT | |
| SCHEMBL15445654 | 0.68 | KMT2A (0.50) | KCNH2NPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL14864560 | 0.67 | KCNH2 (0.45) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 135/4885ADRB3 667/4885NPC1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.